UBS Maintains Buy on Adient, Lowers Price Target to $23
UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and lowers the price target from $29 to $23.
Stocks · News reference
Adient Q3 2026 Earnings Call Transcript
Adient (NYSE:ADNT) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adient Appoints EVP And CFO, Effective November 16, Succeeding Mark Oswald
Adient (NYSE:ADNT), a global leader in automotive seating, today announced that on Oct. 1, 2026, Peter Carlin will be stepping down from Adient's board of directors and joining the company initially as vice
8-K filing — Adient plc (ADNT)
Filed: 2026-09-18 AccNo: 0001670541-26-000105 Size: 519 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits